FDA Approved New Injectable for Schizophrenia
Adults with schizophrenia may soon access a monthly injectable that removes the need for daily oral medication.
Updated on Oct. 10, 2026 in Mental Health
Live Poll
Do you trust that pharmaceutical companies prioritize patient needs when developing new long-term medication treatments?
The U.S. Food and Drug Administration has approved Teva Pharmaceuticals' WELTRUZA, a once-monthly subcutaneous injectable for treating schizophrenia in adults. This new option aims to simplify treatment for the approximately 2.1 million people in the U.S. living with the condition.
Why it matters
The medication addresses common challenges with daily oral adherence, which often contribute to clinical instability and relapse. By providing a once-monthly dosing schedule, it offers a new way for patients to maintain consistent treatment.
The approval is based on the Phase 3 SOLARIS trial, which evaluated the drug in adult patients. Data showed a 4% discontinuation rate due to adverse events in the active treatment group, compared to 5% in the placebo group.
The players
Teva Pharmaceuticals
A global pharmaceutical company that develops treatments for central nervous system disorders and other therapeutic areas.
U.S. Food and Drug Administration
The federal agency responsible for evaluating the safety and efficacy of new medical products.
The details
WELTRUZA is a subcutaneous formulation of olanzapine that utilizes SteadyTeq copolymer technology to provide a controlled, sustained release of the drug. Unlike some other injectable treatments, this medication requires no loading doses, oral supplementation, or post-injection monitoring. It will be available in three dosage strengths: 318 mg, 425 mg, and 531 mg.
Timeline
October 9, 2026: FDA announced approval of WELTRUZA.
Health Landscape
The approval of WELTRUZA follows the clinical data established by the SOLARIS trial. It represents an evolution in schizophrenia management by moving away from daily oral regimens toward long-acting, steady-release technology.
If you or a loved one are managing schizophrenia, this new option may be worth discussing with a doctor to see if a monthly injectable aligns with your treatment goals. The medication is expected to be available in the U.S. in the coming weeks.
The takeaway
The development of long-acting injectables provides an alternative for individuals struggling with daily medication adherence. Speak with your healthcare provider about how different dosing schedules might affect your personal care plan.
Further reading
For more on managing long-term treatment strategies, visit our section on Mental Health.
Live Poll
Do you trust that pharmaceutical companies prioritize patient needs when developing new long-term medication treatments?
